

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

6

Attorney Docket Number

Complete If Known

Application Number	09/770,949- 16/648,619
Filing Date	January 26, 2001
First Named Inventor	
Group Art Unit	1642-1699
Examiner Name	

Attorney Docket Number 02307G-054130US

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)				
50	AA	US 5,231,001	A		Kaplan, et al.	07-27-1993	
11	AB	US 5,753,225	A		Clary, et al.	05-19-1998	
11	AC	US 5,877,305	A		Huston, et al.	03-02-1999	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
50	AD	EPO	92/16559	A1	The United States of America, Secretary	10-01-1992		
11	AE	EPO	WO 92/18149	A1	Regeneron Pharmaceuticals, Inc.	10-29-1992		
11	AF	EPO	0471205	A1	E.R. Squibb & Sons, Inc.	02-19-1992		

Examiner  
Signature

*Stephen Becker*

Date  
Considered

*8/6/07*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1279524 v1

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<i>Complete If Known</i>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	49776,949, 10/648,679	
(use as many sheets as necessary)		Filing Date	January 26, 2001	
Sheet <b>2</b>	of <b>6</b>	First Named Inventor	Group Art Unit	
		Examiner Name	-1642- 1649	
		Attorney Docket Number		02307G-054130US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
S6	AG	Alberts, et al. "Molecular Biology of the Cell" <i>Garland Publishing Inc. (N.Y.)</i> (1989), pp. 333-334.	T <sup>2</sup>	
11	AH	Barde, Y.A. "Tropic Factors and Neuronal Survival" <i>Neuron</i> . (1989) Vol. 2, pp. 1525-1534.		
11	AI	Barker, et al. "The Nerve Growth Factor Receptor: A Multicomponent System that Mediates the Actions of the Neurotrophin Family of Proteins" <i>Molecular and Cellular Biochemistry</i> (1992) Vol. 110, p. 1-15.		
11	AJ	Bolhuis, et al. "Functional Expression of a Single Chain Fv/γ Receptor with Renal Cell Carcinoma Specificity in Activated Human PBL" <i>Third Meeting of the European Working Group of Human Gene Transfer and Therapy, Barcelona, Spain</i> (November 17-20, 1995) <i>Gene Therapy</i> 2 (Suppl. 1):S21 ISSN: 0969-7128.		
11	AK	Bolhuis, et al. "ScFv/gamma Antibody Receptors on Human Cytotoxic T Lymphocytes (CTL) Bind Antigen, Transduce Activation Signals and Respond to Co-regulatory Signals" <i>Joint Meeting of the American Academy of Allergy, Asthma and Immunology, the American Association of Immunologists and the Clinical Immunology Society San Francisco, California, USA</i> (February 21-26, 1997) <i>J. Allergy Clin Immunol</i> 99 (1, Pt 2):S116, 1997 ISSN: 0091-6749.		
11	AL	Casten, et al. "Anti-immunoglobulin Augments the B-Cell Antigen-presentation Function Independently of Internalization of Receptor-Antigen Complex" <i>Proc. Natl. Acad. Sci. USA</i> (September 1985) Vol. 82, pp. 5890-5894.		
11	AM	Collazo, et al. "Cellular Targets and Trophic Functions of Neurotrophin-3 in the Developing Rat Hippocampus" <i>Neuron</i> (October 1992) Vol. 9, pp. 643-656.		
11	AN	Cordon-Cardo, et al. "The <i>trk</i> Tyrosine Protein Kinase Mediates the Mitogenic Properties of Nerve Growth Factor and Neurotrophin-3" <i>Cell</i> (1991) Vol. 66, pp. 173-183.		
11	AO	Drebin, et al. "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies" <i>Cell</i> (July 1985) Vol. 41, pp. 695-706.		

Examiner Signature	<i>Stephen Bude</i>	Date Considered	8/6/07
--------------------	---------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1279524 v1

Please type a plus sign (+) inside this box → [+]

PTO/SB/088 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number  
Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 6

Complete If Known	
Application Number	09/770,940 10/648,619
Filing Date	January 26, 2001
First Named Inventor	
Group Art Unit	1642 1649
Examiner Name	
Attorney Docket Number	02307G-054130US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
S6	AP	Eager, K. "Molecular Characterization of Human <i>trk</i> Proto-oncogene product Monoclonal Antibodies" <i>Onc.</i> (May 1991) Vol. 6(5), pp. 819-824.		
11	AQ	Eide, et al. "Neurotrophins and Their Receptors- Current Concepts and Implications for Neurologic Disease" <i>Exp. Neurol.</i> (1993) Vol. 121, pp. 200-214.		
11	AR	Fan, et al. "Regulation of Epidermal Growth Factor Receptor in NIH3T3/HER14 Cells by Antireceptor Monoclonal Antibodies" <i>J. of Biological Chemistry</i> (October 1993) Vol. 268 (28), pp. 21073-21079.		
11	AS	Fraser, et al. "TCP-11, the Product of a Mouse <i>t</i> -complex Gene, Plays a Role in Stimulation of Capacitation and Inhibition of the Spontaneous Acrosome Reaction" <i>Molecular Reproduction and Development</i> (1997), Vol. 48, pp. 375-382.		
11	AT	Greene, et al. "Establishment of a Noradrenergic Clonal Line of Rat Adrenal Pheochromocytoma Cells Which Respond to Nerve Growth Factor" <i>Proc. Natl. Acad. Sci. USA</i> (1976) Vol. 73, pp. 2424-2428.		
11	AU	Goroff, et al. "Participation of IgGFe Receptor (FeyR) in <i>in vivo</i> B-cell Activation by a Monovalent Anti-IgD Antibody (Ab) Fragment" <i>Fed Proc</i> (1987) Vol. 46(4), pp. 1204.		
11	AV	Hanks, et al. "The Protein Kinase Family: Conserved Features and Deduced Phylogeny of the Catalytic Domains" <i>Science</i> (1988) Vol. 241, pp. 42-52.		
11	AW	Holzer, et al. "A Fusion Protein of IL-8 and a Fab Antibody Fragment Binds to IL-8 Receptors and Induces Neutrophil Activation" <i>Cytokine</i> (March 1996) Vol. 8(3), pp. 214-221.		
11	AX	Holtzman, et al. "p140 <sup>trk</sup> mRNA Marks NGF-Responsive Forebrain Neurons: Evidence that <i>trk</i> Gene Expression is Induced by NGF" <i>Neuron</i> (1992) Vol. 9, pp. 465-478.		
11	AY	Hosang, et al. "Molecular Characteristics of Nerve Growth Factor Receptors on PC12 Cells" <i>J. Biol. Chem.</i> (1985) Vol. 260, pp. 655-662.		
11	AZ	Hutton, et al. "Expression of p75 <sup>NGFR</sup> TrkA and TrkB, mRNA in Rat C6 Glioma and Type I Astrocyte Cultures" <i>J. of Neurosciences Research</i> (1992), Vol. 32, pp. 375-383.		

Examiner Signature	<i>Stephen Gause</i>	Date Considered	8/6/07
--------------------	----------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1279524 v1

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002, OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of 6

Complete If Known

Application Number	09/770,949 10/648,619
Filing Date	January 26, 2001
First Named Inventor	
Group Art Unit	1642 1649
Examiner Name	
Attorney Docket Number	02307G-054130US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
✓	AAA	Jing, et al. "Nerve Growth Factor Mediates Signal Transduction Through <i>trk</i> Homodimer Receptors" <i>Neuron</i> . (1992) Vol.9, pp. 1067-1079.	
11	AAB	Johnson, et al. "Expression and Structure of the Human NGF Receptor" <i>Cell</i> (1986) Vol. 47, pp. 545-554.	
11	AAC	Kaplan, et al. "The <i>trk</i> Proto-Oncogene Product: A Signal Transducing Receptor for Nerve Growth Factor" <i>Science</i> (1991) Vol. 252, pp.554-558.	
11	AAD	Kaplan, et al. "Tyrosine Phosphorylation and Tyrosine Kinase Activity of the <i>trk</i> Proto-oncogene Product Induced by NGF" <i>Nature</i> (1991) Vol 350, pp. 158-160.	
11	AAE	Klein, et al. " <i>trkB</i> , A Novel Tyrosine Protein Kinase Receptor Expressed During Mouse Neural Development" <i>Embro. J.</i> (1989) Vol. 8(12), pp. 3701-3709.	
11	AAF	Klein, et al. "The <i>trk</i> Proto-oncogene Encodes a Receptor for Nerve Growth Factor" <i>Cell</i> (1991) Vol. 65, pp. 189-197.	
11	AAG	Knusel, et al. "K-252 Compounds: Modulators of Neurotrophin Signal Transduction" <i>J. of Neurochemistry</i> (1992) Vol. 59, pp. 1987.	
11	AAH	Korschning, S. "The Neurotrophic Factor Concept: A Reexamination" <i>Neurosci.</i> (1993) Vol. 13, pp. 2739-2748.	
11	AAI	Lamballe, et al. " <i>trkC</i> , A New Member of the <i>trk</i> Family of Tyrosine Protein Kinases, is a Receptor for Neurotrophin-3" <i>Cell</i> (1991) Vol. 66, pp. 967-979.	
✓	AAJ	Levi-Montalcini, R. "The Nerve Growth Factor 35 Years Later" <i>Science</i> (1987) Vol. 237, pp. 1154-1162.	
11	AAK	Loeb, et al. "NGF and Other Growth Factors Induce an Association Between ERK1 and the NGF Receptor, gp140 <sup>proto<trk></trk></sup> " <i>Neuron</i> (1992) Vol. 9, pp. 1053-1065.	
11	AAL	Martin-Zanca, et al. "Molecular and Biochemical Characterization of the Human <i>trk</i> Proto-Oncogene" <i>Mol. Cell. Biol.</i> (1989) Vol. 9, pp. 24-33.	
11	AAM	Martin-Zanca, et al. "Expression of the <i>trk</i> Proto-Oncogene is Restricted to the Sensory Cranial and Spinal Ganglia of Neural Crest Origin in Mouse Development" <i>Genes Dev.</i> (1990) Vol. 4, pp. 683-694.	

Examiner  
Signature

Stephen Buckley

Date  
Considered

8/6/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1279524 v1

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Compleat If Known</b>	
(use as many sheets as necessary)		Application Number	109770-949 16/648,679
		Filing Date	January 26, 2001
		First Named Inventor	
		Group Art Unit	1642 1679
		Examiner Name	
Sheet	5	of	6
		Attorney Docket Number	02307G-054130US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
SG	AAN	Meakin, et al. "Molecular Investigations on the High-Affinity Nerve Growth Factor Receptor" <i>Neuron</i> (1991) Vol. 6, pp. 153-163.		
Y	AAO	Middlemas, et al. "trkB, a Neural Receptor Protein-Tyrosine Kinase: Evidence for a Full-Length and Two Truncated Receptors" <i>Mol. Cell. Biol.</i> (1991) Vol. 11, pp. 143-143.		
Y	AAP	Obermeirer, et al. "Tyrosine 785 is a Major Determinant of Trk- Substrate Interaction" <i>Embro. J.</i> (1993) Vol. 12, pp. 933-941.		
Y	AAQ	Ohmichi, et al. "Nerve Growth Factor Binds to the 140 kd trk Proto-Oncogene Product and Stimulates its Association with the src Homology Domain of Phospholipase C y1" <i>Biochem. Biophys. Res. Commun.</i> (1991) Vol. 179, pp. 217-223.		
Y	AAR	Ohmichi, et al. "Activation of Phosphatidylinositol-3 by Nerve Growth Factor Involves Indirect Coupling of the trk Proto-Oncogene with src Homology 2 Domains" <i>Neuron</i> (1992) Vol. 9, pp. 769-777.		
Y	AAS	Persson, et al. "Role and Expression of Neurotrophins and the trk Family of Tyrosine Kinase Receptors in Neural Growth and Rescue After Injury" <i>Current Opinion in Neurology and Neurosurgery</i> (1993) Vol. 6, p. 11.		
Y	AAT	Pulido, et al. "Dtrk, A Drosophila Gene Related to the trk Family of Neurotrophin Receptors, Encodes A Novel Class of Neural Cell Adhesion Molecule" <i>Ebro</i> (1992) Vol. 11, pp. 391-404.		
Y	AAU	Radeke, et al. "Gene Transfer and Molecular Cloning of the Rat Nerve Growth Factor Receptor" <i>Nature</i> (1987) Vol. 325, 593-597.		
Y	AAV	Radeke, et al. "Analytical Purification of the Slow, High Affinity NGF Receptor: Identification of a Novel 135 kd Polypeptide" <i>Neuron</i> (1991) Vol. 7, pp. 141-150.		
Y	AAW	Ringden, et al. "Mitogenic Properties of Fab and F(ab') <sub>2</sub> Fragments of Rabbit Anti-Human $\beta_2$ -Microglobulin for Human Lymphocytes" <i>J. Immunol.</i> (1977) Vol. 6, pp. 281-289.		
Y	AAX	Schechter, et al. "Novel Roles for Neurotrophins are Suggested by BDNF and NT-3 mRNA Expression in Developing Neurons" <i>Cell</i> (1981) Vol. 24, pp. 867-874.		

Examiner Signature	<i>Stephen Gusek</i>	Date Considered	8/6/07
--------------------	----------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1279524 v1

Please type a plus sign (+) inside this box →

PTO/SB/088 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	09/770,949 16/698,619
(use as many sheets as necessary)		Filing Date	January 26, 2001
Sheet 6 of 6		First Named Inventor	
		Group Art Unit	1642 1649
		Examiner Name	
		Attorney Docket Number	02307G-054130US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
SG	AAY	Schecterson, et al. "Novel Roles for Neurotrophins are Suggested by BDNF and NT-3 mRNA Expression in Developing Neurons" <i>Neuron</i> (1992) Vol. 9, pp. 449-463.		
11	AAZ	Schneider, et al. "A Novel Molecular Mosaic of Cell Adhesion Motifs in the Extracellular Domains of the Neurogenic <i>trk</i> and <i>trkB</i> Tyrosine Kinase Receptors" <i>Oncogene</i> (1991) Vol. 6, pp. 1807-1811.		
11	AAAA	Schodin, et al. "Binding Affinity and Inhibitory Properties of a Single-Chain Anti-T Cell Receptor Antibody" <i>The J. of Biological Chemistry</i> (December 1993) Vol. 268(34), pp. 25722-25727.		
11	AAAB	Steele-Perkins, et al. "Insulin-mimetic Anti-insulin Receptor Monoclonal Antibodies Stimulate Receptor Kinase Activity in Intact Cells" <i>J. Biol. Chem.</i> (June 1990) Vol. 265(16), pp. 9458-9463.		
11	AAAC	Sutter, et al. "Nerve Growth Factor Receptors" <i>J. Biol. Chem.</i> (1979) Vol. 254, pp. 5972-5982.		
11	AAAD	Vetter, et al. "Nerve Growth Factor Rapidly Stimulates Tyrosine Phosphorylation Phospholipase C-γ1 by a Kinase Activity Associated with the Product of the <i>trk</i> Proto-oncogene" <i>Proc. Natl. Acad. Sci. USA</i> (1991) Vol. 88, pp. 5650-5654.		
11	AAAE	Weskamp, et al. "Evidence that Biological Activity of NGF is Mediated Through a Novel Subclass of High Affinity Receptors" <i>Neuron</i> . (1991) Vol. 6, pp. 649-663.		
11	AAAF	Wheeler, et al. J. "Spatiotemporal Patterns of Expression of NGF and the Low-Affinity NGF Receptor in Rat Embryos Suggest Functional Roles in Tissue Morphogenesis and Myogenesis" <i>Neurosci.</i> (1992) Vol. 12, pp. 930-945.		
11	AAAG	Wyatt, et al. "Expression of the NGF Receptor Gene in Sensory Neurons and Their Cutaneous Targets Prior to and During Innervation" <i>Neuron</i> . (1990) Vol. 4, pp. 421-427.		
11	AAAH	Xie, et al. "Direct Demonstration of MuSK Involvement in Acetylcholine Receptor Clustering Through Identification of Agonist ScFv" <i>Nature Biotechnology</i> (August 1997) Vol. 15, pp. 768-771.		

Examiner Signature	Stephens, Guelde	Date Considered	8/6/07
--------------------	------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1278524 v1